# (CONVENIENCE TRANSLATION OF THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH)

MLP SAĞLIK HİZMETLERİ A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDED 1 JANUARY - MARCH 31, 2021

## CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH

## CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 1 JANUARY - MARCH 31, 2021

INDEX	P	AGE
CONSOL	IDATED INTERIM STATEMENT OF FINANCIAL POSITION	1-2
	IDATED INTERIM STATEMENT OF PROFIT OR LOSS HER COMPREHENSIVE INCOME	3
CONSOL	IDATED INTERIM STATEMENT OF CHANGES IN EQUITY	4
CONSOL	IDATED INTERIM STATEMENT OF CASH FLOWS	5-6
NOTES 1	TO THE CONSOLIDATED FINANCIAL STATEMENTS	7-41
NOTE 1	ORGANIZATION AND OPERATIONS OF THE GROUP	
NOTE 2	BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS	
NOTE 3	RELATED PARTY DISCLOSURES	
NOTE 4	CASH AND CASH EQUIVALENTS	
NOTE 5	FINANCIAL INSTRUMENTS	
NOTE 6	TRADE RECEIVABLES AND PAYABLES	
NOTE 7	OTHER RECEIVABLES AND PAYABLES	
NOTE 8	INVENTORIES	
NOTE 9	PREPAID EXPENSES AND DEFERRED INCOME	
NOTE 10	PROPERTY, EQUIPMENT AND OTHER INTANGIBLE ASSETS	
NOTE 11	RIGHT OF USE ASSETS	
NOTE 12	PAYABLES FOR EMPLOYEE BENEFITS	
NOTE 13	OTHER ASSETS AND LIABILITIES	
NOTE 14	PROVISIONS	
NOTE 15	COMMITMENTS	
NOTE 16	SHARE CAPITAL/OTHER RESERVES	
NOTE 17	REVENUE	
NOTE 18	OPERATING EXPENSES	
NOTE 19	OTHER INCOME AND EXPENSE FROM OPERATING ACTIVITIES	
NOTE 20	INCOME AND EXPENSES FROM INVESTING ACTIVITIES	
NOTE 21	FINANCE EXPENSES	
NOTE 22	TAXES ON INCOME (DEFERRED TAX ASSET AND LIABILITIES INCLUDED)	
NOTE 23	EARNINGS PER SHARE	
NOTE 24	FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES	
NOTE 25	EVENTS AFTER THE REPORTING PERIOD	

APPENDIX I EARNINGS BEFORE INTEREST TAXES DEPRECIATION AND AMORTISATION ("EBITDA")

## CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION AS AT MARCH 31, 2021 (Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

		Unaudited March 31,	Audited December 31,
	Notes	2021	2020
Assets			
Current assets		2,508,023	2,185,278
Cash and cash equivalents	4	579,247	374,997
Trade receivables	6	1,216,710	1,155,116
- Due from related parties	3	9,225	23,654
- Trade receivables from third parties		1,207,485	1,131,462
Other receivables	7	77,923	84,367
- Due from related parties	3	44,715	41,059
- Other receivables from third parties		33,208	43,308
Inventories	8	108,982	113,482
Prepaid expenses	9	478,979	414,263
Other current assets	13	46,182	43,053
Non-current Assets:		2,416,977	2,386,572
Trade receivables		1,053	1,053
Other receivables	7	2,805	2,740
Property plant and equipment	10	761,462	764,245
Intangible assets		677,584	676,849
- Goodwill		38,661	38,661
- Other intangible assets	10	638,923	638,188
Right of use assets	11	295,601	257,440
Prepaid expenses	9	299,619	282,714
Deferred tax assets	22	378,853	401,531
TOTAL ASSETS		4,925,000	4,571,850

## CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION AS AT MARCH 31, 2021 (Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

	Notes	Unaudited March 31, 2021	Audited December 31, 2020
Liabilities and equity			
Current Liabilities:		2,633,687	2,386,700
Short term borrowings	5	415,859	363,743
Short term portion of long term borrowings	5	440,382	392,485
Obligations under finance leases	5	107,669	102,825
Short term lease liabilities	5	119,705	118,792
Trade payables	6	1,076,510	987,130
- Due to related parties	3	14,019	18,206
- Trade payables to third parties		1,062,491	968,924
Payables related to employee benefits	12	96,814	91,379
Other payables	7	57,593	51,684
- Due to related parties	3	799	799
- Other payables to third parties		56,794	50,885
Deferred income	9	259,397	221,497
Short term provisions		46,826	39,457
- Short term provisions for employment benefits	12	21,758	19,090
- Other short term provisions	14	25,068	20,367
Current tax liabilities	22	12,932	17,708
Non-current Liabilities:		1,865,458	1,836,293
Long term borrowings	5	961,766	944,203
Obligations under finance leases	5	76,657	93,239
Long term lease liabilities	5	507,624	476,310
Other payables		103,317	106,471
- Other payables to third parties	7	103,317	106,471
Deferred income	9	2,122	2,211
Long term provisions		30,522	30,207
<ul> <li>Long term provisions for employee benefits</li> </ul>	12	30,522	30,207
Deferred tax liabilities	22	183,450	183,652
EQUITY:		425,855	348,857
<b>Equity Attributable to the Owner of the Company</b>	:	345,846	282,387
C1	1.0	200.027	200.027
Share capital	16	208,037	208,037
Share premium	16	556,162	556,162
Other comprehensive income or expenses			
that will not be reclassified			4.004
subsequently to profit or loss	4.5	4,146	1,896
- Revaluation reserve	16	37,747	37,747
- Accumulated gain/(loss) on remeasurement of		(00.101)	/a= a= ··
defined benefit plans		(33,601)	(35,851)
Restricted reserves	16	10,260	10,260
Accumulated deficit		(498,407)	(558,898)
Net profit for the period		65,648	64,930
Non-controlling interest		80,009	66,470
TOTAL LIABILITIES AND EQUITY		4,925,000	4,571,850

## CONSOLIDATED INTERIM STATEMENT OF PROFIT OR LOSS FOR THE THREE-MONTH PERIOD ENDED 1 JANUARY - MARCH 31,2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

	Notes	Unaudited March 31, 2021	Unaudited March 31, 2020
Profit or loss			
Revenue	17	1,211,304	978,870
Cost of sales (-)	17	(908,256)	(750,026)
Gross profit		303,048	228,844
General administration expenses (-)	18	(84,774)	(73,976)
Other income from operating activities	19	84,855	82,219
Other expenses from operating activities (-)	19	(57,029)	(67,328)
Operating profit		246,100	169,759
Income from investing activities	20	234	82,462
Expense from investing activities (-)	20	(2)	(98)
Operating profit before finance expenses		246,332	252,123
Finance expenses (-)	21	(131,606)	(165,606)
Net profit before tax		114,726	86,517
Tax income/(expense) from operations		(34,845)	(25,147)
Current tax expense	22	(12,932)	(4,133)
Deferred tax income/(expense)	22	(21,913)	(21,014)
Net profit		79,881	61,370
Non-controlling interest		14,233	11,004
Equity holders of the parent		65,648	50,366
		79,881	61,370
Basic gain/(loss) per share	23	0.32	0.24
Other comprehensive income/(expense)		2,250	(189)
Items that will not be reclassified			
subsequently to profit or loss		2 012	(226)
Remeasurement of defined benefit plans Income tax relating to items that will not be		2,813	(236)
reclassified subsequently		(563)	47
Total comprehensive income/(loss)		82,131	61,181
Total comprehensive income/(loss) distribution:			
Non-controlling interest		14,233	11,004
Equity holders of the parent		67,898	50,177

The accompanying notes form an integral part of these consolidated financial statements.

## CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY FOR THE THREE-MONTH PERIOD ENDED 1 JANUARY - MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

Accumulated other comprehensive income or expenses that will not be reclassified subsequently to profit or

				(loss)							
		Share Share capital premium		Share revaluation defin		ted loss on urement of ned benefit Legal Accumulated plans reserves deficit		Net profit/ (loss) for the period	Accumulated Profit Attributable to equity holders of the Parent	Non-controlling interest	Total
Balance as at January 1, 2020	208,037	556,162	37,747	(23,306)	10,260	(595,149)	36,251	230,002	8,403	238,405	
Other comprehensive loss for the period, net of tax Net profit/(loss) for the period	- -	- -	- -	(189)	- -	- -	50,366	(189) 50,366	11,004	(189) 61,370	
Total comprehensive loss for the period	-	-	-	(189)	-	-	50,366	50,177	11,004	61,181	
Transfers	-	-	-	-	-	36,251	(36,251)	-	-	-	
Balance as at March 31, 2020	208,037	556,162	37,747	(23,495)	10,260	(558,898)	50,366	280,179	19,407	299,586	
Balance as at January 1, 2021	208,037	556,162	37,747	(35,851)	10,260	(558,898)	64,930	282,387	66,470	348,857	
Other comprehensive loss for the period, net of tax Net profit/(loss) for the period	-	-	-	2,250	-	-	- 65,648	2,250 65,648	14,233	2,250 79,881	
Total comprehensive loss for the period Transfers Dividend Distribution	-	-	<u>.</u> -	2,250	<u>.</u> -	64,930 (4,439)	<b>65,648</b> (64,930)	<b>67,898</b> - (4,439)	14,233 - (694)	<b>82,131</b> - (5,133)	
Balance as at March 31, 2021	208,037	556,162	37,747	(33,601)	10,260	(498,407)	65,648	345,846	80,009	425,855	

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021 (Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

	Notes	Unaudited January 1 - March 31, 2021	Unaudited January 1 - March 31, 2020
Cash flows from operating activities		322,441	205,406
Net profit/(loss) for the period		79,881	61,370
Profit (loss) continuing operations		249,236	170,009
Adjustments related to depreciation and amortization expens	es 10.11	72,855	62,474
Adjustments related to impairment (reversal)	10,11	274	596
Adjustments related to impairment (reversal) of receivable	s 6	274	596
Adjustments related to provisions	5	16,519	2,711
Adjustments related to (reversal) of		10,619	2,711
provision for employment benefits		8,418	2.902
Adjustments related to lawsuit (reversal) of provision for	lawsuit	8,101	(191)
Adjustments related to interest (income) expense		117,991	103,310
Adjustments related to interest income	19	(4,517)	(5,139)
Adjustments related to interest expense	21	122,508	108,449
Adjustments related to gain (loss) on fair value	21	,	(11,287)
Loss (gain) arising on derivatives	21	-	(11,287)
Adjustments related to tax (gain) loss	22	34.845	25.147
Other adjustments related to non-cash items		6,984	69,422
Adjustments regarding to (gain) loss on sale of bargain purcl	hase 26	, <u>-</u>	(81,980)
Adjustments regarding to (gain) loss on sale of fix assets		(232)	(384)
Adjustments regarding to (gain) loss on sale of tangible asse	ts	(232)	(384)
Changes in working capital		16,180	(20,110)
Adjustments related to increase in trade receivables		(55,505)	(76,886)
Adjustments related to increase in inventories		4,500	(27,276)
Adjustments related to increase in trade payables		90,833	48,392
Adjustments related to increase in other payables from oper	ations	45,142	70,084
Adjustments related to other (increase) decrease in working		(68,790)	(34,424)
Adjustments related to increase in other payables from othe		(68,790)	(34,424)
regulations remove to inference in outer payments from our	1 45500	(00,750)	(8 :, 12 :)
Cash generated from operations		345,297	211,269
Payments related with provision for employee benefits		(2,623)	(1,738)
Tax paid	22	(17,708)	(4,654)
Payments for other provisions		(2,541)	-
Other cash inflows (outflows)	6	16	529

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021 (Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

	Notes	Unaudited January 1 - March 31, 2021	Audited January 1 - March 31, 2020
Cash flows from investing activities		(53,968)	(40,009)
Proceeds from sales of property, plant, equipment			
and intangible assets		272	789
Proceeds from sales of property, plant, equipment	10	272	789
Payment for purchase of property, plant			
and equipment, intangible assets		(43,459)	(36,041)
Payment for purchase of property, plant and equipment	10	(40,361)	(26,278)
Payment for purchase of intangible assets	10	(3,098)	(9,763)
Cash payments for capital expenditures	9	(15,298)	(9,896)
Interest received	19	4,517	5,139
Cash flows from financing activities		(64,223)	(85,414)
Proceeds from bank loans		634,489	256,786
Proceeds from borrowings		414,489	155,235
Proceeds from bonds		220,000	101,551
Repayment of lease liabilities		(75,281)	(67,113)
Bank borrowings paid		(529,306)	(173,639)
Cash used for repayment of borrowings		(441,395)	(72,088)
Cash used for repayment of bonds		(87,911)	(101,551)
Repayment of obligations under finance leases		(24,857)	(20,455)
Interest paid		(64,135)	(80,993)
Dividend paid		(5,133)	<u> </u>
Net increase (decrease) in cash and cash equivalents		204,250	79,983
Cash and cash equivalents at the beginning of the period	4	374,997	305,663
Cash and cash equivalents at the end of the period	4	579,247	385,646

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

#### NOTE 1 - ORGANIZATION AND OPERATIONS OF THE GROUP

MLP Sağlık Hizmetleri A.Ş. ("MLP Sağlık") has started its healthcare services operations in 1993, with the opening of Sultangazi Medical Center within the structure of Yükseliş Sağlık Hizmetleri Gıda Tekstil San. Ltd. Şti. in which Muharrem Usta is the majority shareholder. Following this, in 1995, it continues its operations, with the opening of Fatih Hospital under the legal entity of Saray Sağlık Hizmet Ticaret ve Sanayi A.Ş. in which Muharrem Usta was the majority shareholder. In 2005, with the establishment of MLP Sağlık, Fatih and Sultangazi Hospitals were merged under the legal entity of MLP Sağlık.

As of March 31, 2021, MLP is the holding company of 17 subsidiaries (December 31, 2020: 17) (collectively referred as the "Group"), each operating in the healthcare sector in Turkey.

The Company's head office is located in Otakçılar Caddesi No 78 3450, Eyüp, İstanbul.

The Group has an agreement with the Social Security Institution of Turkey (the "SSI") which includes service commitment in all branches disclosed in the Operations Approval Document. SSI is a state enterprise which pays the healthcare expenditures of the citizens of Turkey who are members of the social security system based on the law numbered 5510, and manages social security premiums and short and long term insurance expenses. According to the agreement, the Group is obliged to provide the healthcare services and to issue invoices to the SSI and patients in line with the Communiqué of Health Services published by the SSI. This transaction is performed through Medula, a web based software system, by assessing the right of the patient and obtaining provisions. As a result of the assessment the expenses relating to patients with no SSI, coverage is not charged to SSI. The healthcare expenses provided to the patients are invoiced based on the terms of the Communiqué of Health Services. In this Communiqué SSI determined a price list based on the treatments provided. Invoices are issued based on the price list announced by the Communiqué. SSI has the right not to pay the invoice or make a deduction if the treatments provided are not in compliance with the terms.

The Company is registered to the Capital Markets Board ("CMB") and its shares have been quoted on the Borsa İstanbul A.Ş. ("BİAŞ or "Borsa" or "BİST") since February 13, 2018. In accordance with the resolution numbered 21/655 on July 23, 2010 of CMB; according to the records of Central Registry Agency (CRA); shares representing 33.36% as of March 31 2021, of MLP Sağlık are accepted as "in circulation". As of April 3, 2020, this ratio is 33.36% (Note 16).

#### Approval of financial statements

Board of Directors has approved the financial statements and delegated authority for publishing it on May 6, 2021.

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

### NOTE 1 - ORGANIZATION AND OPERATIONS OF THE GROUP (Continued)

As of March 31, 2021 the subsidiaries of the Company are:

of operation Name Sentez Sağlık Hizmetleri A.Ş. ("Sentez Hastaneleri") Batman - İzmir - Gaziantep Temar Tokat Manyetik Rezonans Sağlık Hizmetleri ve Turizm A.S. ("Tokat Hastanesi") Tokat Samsun Medikal Grup Özel Sağlık Hizmetleri A.Ş. ("Samsun Hastanesi") Samsun-İstanbul Özel Samsun Medikal Tıp Merkezi ve Sağlık Hizmetleri Tic. Ltd. Şti. ("Samsun Tip Merkezi") Samsun Kuzey Medikal Pazarlama İnşaat Taşımacılık San. ve Tic. Ltd. Şti. ("Kuzey") Ankara Artımed Medikal Sanayi ve Ticaret Ltd. Şti. ("Artımed") Ankara MS Sağlık Hizmetleri Ticaret A.Ş. ("MS Sağlık") Ankara Mediplaza Sağlık Hizmetleri Ticaret A.Ş. ("Mediplaza") Gebze - İzmit 21. Yüzyıl Anadolu Vakfı ("21.Yüzyıl Anadolu Vakfı") İstanbul BTN Sigorta Aracılık Hizmetleri A.Ş. ("BTN Sigorta") İstanbul Endmed Endüstri Medikal Malzeme Cihazlar San. Tic. Ltd. Şti. ve Kuzey Medikal Pazarlama İnşaat Taşımacılık San. ve Tic. Ltd. Şti. İş Ortaklığı ("Kuzey Hastaneler Birliği" ya da "KHB") Sotte Sağlık Temizlik Yemek Medikal Turizm İnsaat San. ve Tic. A.Ş. İstanbul ("Sotte Sağlık Temizlik Yemek") İstanbul - Ankara MA Group Sağlık ve Danışmanlık Hizmetleri Ticaret A.Ş. ("MA Group") İstanbul BTN Asistans Sağlık Hizmetleri A.Ş. ("BTN Asistans") İstanbul

Location and base

İstanbul

İstanbul

Gaziantep

#### NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS

İstanbul Meditime Sağlık Hizmetleri Ticaret Ltd. Sti. ("Meditime Sağlık")

MLP Gaziantep Sağlık Hizmetleri Anonim Şirketi ("MLP Gaziantep Sağlık")

#### 2.1 Basis of Presentation

#### Statement of Compliance with TFRS

BTR Sağlık Hizmetleri A.Ş. ("BTR Sağlık")

The condensed consolidated financial statements of the Group have been prepared in accordance with the Turkish Financial Reporting Standards, ("TFRS") and interpretations as adopted in line with international standards by the Public Oversight Accounting and Auditing Standards Authority of Turkey ("POA") in line with the communiqué numbered II-14.1 "Communiqué on the Principles of Financial Reporting In Capital Markets" ("the Communiqué") announced by the Capital Markets Board of Turkey ("CMB") on June 13, 2013 which is published on Official Gazette numbered 28676.

The Company prepared its condensed interim financial statements for the period ended 31 March 202 in accordance with ("IAS") 34 "Interim Financial Reporting". The condensed interim financial statements and its accompanying notes are presented in compliance with the format recommended by CMB including its mandatory information. In compliance with the IAS 34, entities have preference in presenting their interim financial statements whether full set or condensed. In this framework, the Company preferred to present its interim financial statements in condensed.

Interim condensed financial statements of the Group do not include all the information and disclosures required in the annual financial statements, therefore should be read in conjunction with the Company's annual financial statements as of 31 December 2020.

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

#### NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 2.1 Basis of Presentation (Continued)

### Currency Used

Each entity in the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency. For the purpose of the consolidated financial statements, the results and financial position of each entity consolidated are expressed in Turkish Lira ("TL"), which is the functional currency of the Company and all its subsidiaries and the presentation currency of the Group.

#### Inflation accounting

In accordance with the CMB's decision dated March 17, 2005 and numbered 11/367, for companies operating in Turkey and preparing financial statements in accordance with the Turkish Accounting Standards, the application of inflation accounting has been terminated as of January 1, 2005. Accordingly, as of January 1, 2005, "Financial Reporting in High Inflation Economies" Standard ("TAS 29") has not been applied.

### Restatement and errors in the accounting policies and estimates

The Group's consolidated financial statements have been prepared in comparison with the previous period in order to give accurate trend analysis regarding the financial position and performance. Where necessary, comparative figures have been reclassified to conform to the presentation of the current period consolidated financial statements and significant changes are explained.

In the previous year, the Group had not reclassified certain comparative balances in order to conform to current year's presentation in the consolidated financial statements.

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

### NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 2.1 Basis of Presentation (Continued)

### **Basis of Consolidation**

The details of the Company's subsidiaries as at March 31, 2021 and December 31, 2020 are as follows:

	Proportion of ownership and voting power held(%)					
	Place of	March 31,	December 31,	Principal		
Subsidiaries incorporat	tion and operation	2021	2020	activity		
Sentez Hastaneleri Batma	an-İzmir-Gaziantep	56.00%	56.00%	Hospital services		
Tokat Hastanesi	Tokat	58.84%	58.84%	Hospital services		
Samsun Hastanesi	Samsun	80.00%	80.00%	Hospital services		
Samsun Tıp Merkezi (1)	Samsun	100.00%	100.00%	Hospital services		
MS Sağlık	Ankara	75.00%	75.00%	Hospital services		
Mediplaza	Gebze-İzmit	75.00%	75.00%	Hospital services		
MA Group (3)	İstanbul	75.00%	51.00%	Hospital services		
BTR Sağlık Hizmetleri	İstanbul	100.00%	100.00%	Hospital services		
Meditime Sağlık	İstanbul	100.00%	100.00%	Hospital services		
MLP Gaziantep Sağlık	Gaziantep	60.00%	60.00%	Hospital services		
Sotte Sağlık Temizlik Yemek	İstanbul-Ankara	100.00%	100.00%	Ancillary services		
Kuzey	Ankara	100.00%	100.00%	Ancillary services		
Artımed	Ankara	100.00%	100.00%	Ancillary services		
21. Yüzyıl Anadolu Vakfı (1) (2	) İstanbul	100.00%	100.00%	Ancillary services		
BTN Sigorta (4)	İstanbul	100.00%	100.00%	Ancillary services		
Kuzey Hastaneler Birliği ("KHE	3") İstanbul	99.90%	99.90%	Ancillary services		
BTN Asistans (4)	İstanbul	100.00%	100.00%	Ancillary services		

- (1) Represents voting power held.
- (2) In 2011, the Group with the help of its real person shareholders decided to establish a medical university. Based on current legislation, foundations have to be owned by real persons rather than companies and since MLP could not be the shareholder of an association, Muharrem Usta, one of the shareholders in the company, was assigned as the chairman of the board of the foundation. The purpose of the foundation is to establish a medical university in order to align one of the hospitals of the Group to that university. Although, MLP has no shareholder interest in the foundation, the financial statements of the foundation are consolidated to the financial statements in accordance with IFRS 10 as the Company achieved the control by having power and the ability to use its power on the future benefit and cost of the foundation. In addition, the Company has rights to the financial and operating policies
- (3) The Company took liquidation decision on December 25, 2017.
- (4) The Company has decided to cease all activities as of September 18, 2020 on September 15, 2020.

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

#### NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 2.1 Basis of Presentation (Continued)

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company:

- Has power over the investee,
- Is exposed, or has rights, to variable returns from its involvement with the investee and
- Has the ability to use its power to affect its returns.

The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above.

In cases where the Company has no majority voting rights on the company/asset invested, it still has the control power over that company/asset if the Company alone has sufficient voting rights to manage the investment operations of that company/asset. The Company considers all events and requirements including the items listed below to evaluate if its voting power is sufficient to get control power in an investment:

- The comparison of the Company's voting right and other shareholders' voting rights;
- Potential voting rights of the Company and other shareholders;
- Rights emerging from other agreements upon contracts;
- Other events and requirements showing the potential power of the Company in managing operation decisions (including the voting held on prior period general assemblies).

Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date the Company gains control until the date when the Company ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income are attributed to the owners of the Company and to the non-controlling interests. Total comprehensive income of subsidiaries is attributed to the owners of the Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

Where necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies in line with those used by other members of the Group.

All intra-group assets and liabilities, equities, income and expenses and cash flows resulting from of Group companies' transactions are eliminated on consolidation.

#### Changes in the Group's ownership interests in existing subsidiaries

Changes in the Group's ownership interests in subsidiaries that do not result in the Group losing control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the Group's interests and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to owners of the Company.

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

#### NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 2.1 Basis of Presentation (Continued)

When the Group loses control of a subsidiary, a gain or loss is recognised in profit or loss and is calculated as the difference between (i) the aggregate of the fair value of the consideration received and the fair value of any retained interest and (ii) the previous carrying amount of the assets (including goodwill), and liabilities of the subsidiary and any non-controlling interests. All amounts previously recognised in other comprehensive income in relation to that subsidiary are accounted for as if the Group had directly disposed of the related assets or liabilities of the subsidiary (i.e. reclassified to profit or loss or transferred to another category of equity as specified/permitted by applicable IFRSs). The fair value of any investment retained in the former subsidiary at the date when control is lost is regarded as the fair value on initial recognition for subsequent accounting under IAS 39, when applicable, the cost on initial recognition of an investment in an associate or a joint venture.

### 2.2 Changes in Accounting Policies

Significant changes made in accounting policies are applied retrospectively and prior year financial statements are restated. In current period, the Group has no changes in its accounting policies other than the change disclosed in Note 2.1.

### 2.3 Changes in the Accounting Estimates and Errors

If changes in accounting estimates are for only one period, changes are applied on the current year but if the changes in accounting estimates are for the following periods, changes are applied both on the current and the following years prospectively. In the current period, the Group has no changes in the accounting estimates and errors.

The Group has made adjustments in the previous period financial statements resulting from the first application of the "IFRS 16 Leases" Standard. The Group applied retrospectively the effects of these adjustments to the consolidated statement of profit or loss for the three-month interim period ended 31 March 2021, which is the earliest period presented in accordance with IAS 8 "Changes in the Accounting Estimates and Errors".

### 2.4 Significant Accounting Estimates and Decisions

Preparation of consolidated financial statements requires management to make estimations and assumptions which may affect the reported amounts of assets and liabilities as of the statement of financial position date, the disclosure of contingent assets and liabilities and the reported amounts of income and expenses during the financial period. The accounting assessments, estimates and assumptions are reviewed considering past experiences, other factors and reasonable expectations about future events under current conditions. Although the estimations and assumptions are based on the best estimates of the management's existing incidents and operations, they may differ from the actual results.

### Effect of Covid 19 Outbreak on Group Activities

Covid-19 infection (Coronavirus) which appeared first in China in December 2019 and affected the world as of March 2020 was declared as a global pandemic by the World Health Organization as of March 11, 2020. Several cases have been announced since March 2020 in Turkey.

In order to prevent the Covid-19 epidemic and the spread of the epidemic, the Ministry of Health General Directorate of Health Services published its memorandum on "Pandemic Hospitals" numbered 14500235-403.99 on March 20,2020. According to Article 1 of memorandum, all foundation hospitals and private hospitals are obliged to treat the patient until the diagnosis of Covid-19 becomes definite. According to the memorandum, when MLP Sağlık Hizmetleri and its subsidiaries are evaluated, all hospitals except "Çanakkale Hospital" have become "Pandemi Hospital". In this context, all hospitals under the management of Group have taken all precautions regarding the Covid-19 outbreak and provided the necessary environment for the health of our employees and the safe treatment of our patients. The Company Management monitors the financial and operational impacts of the epidemic and makes relevant assessments.

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

#### NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

- 2.5 Changes in Accounting Picies
- (a) Standards, amendments and interpretations that are issued but not effective as at 31 March 2021:
- Amendment to IFRS 16, 'Leases' Covid 19 related rent concessions; effective from Annual periods beginning on or after 1 June 2020. As a result of the coronavirus (COVID 19) pandemic, rent concessions have been granted to lessees. Such concessions might take a variety of forms, including payment holidays and deferral of lease payments. On 28 May 2020, the IASB published an amendment to IFRS 16 that provides an optional practical expedient for lessees from assessing whether a rent concession related to COVID 19 is a lease modification. Lessees can elect to account for such rent concessions in the same way as they would if they were not lease modifications. In many cases, this will result in accounting for the concession as variable lease payments in the period(s) in which the event or condition that triggers the reduced payment occurs.
- IFRS 17, 'Insurance contracts'; effective from annual periods beginning on or after 1 January 2021. This standard replaces IFRS 4, which currently permits a wide variety of practices in accounting for insurance contracts. IFRS 17 will fundamentally change the accounting by all entities that issue insurance contracts and investment contracts with discretionary participation features.

Amendments to IAS 1, "Presentation of financial statements' on classification of liabilities"; effective from 1 January 2022. These narrow-scope amendments to IAS 1, 'Presentation of financial statements', clarify that liabilities are classified as either current or non-current, depending on the rights that exist at the end of the reporting period. Classification is unaffected by the expectations of the entity or events after the reporting date (for example, the receipt of a waiver or a breach of covenant). The amendment also clarifies what IAS 1 means when it refers to the 'settlement' of a liability.

- A number of narrow scope amendments to IFRS 3, IAS 16, IAS 37 and some annual improvements on IFRS 1, IFRS 9, IAS 41 and IFRS 16; effective from Annual periods beginning on or after 1 January 2022.
  - **Amendments to IFRS 3**, "Business combinations" update a reference in IFRS 3 to the Conceptual Framework for Financial Reporting without changing the accounting requirements for business combinations.
  - **Amendments to IAS 16**, "Property, plant and equipment" prohibit a company from deducting from the cost of property, plant and equipment amounts received from selling items produced while the company is preparing the asset for its intended use. Instead, a company will recognise such sales proceeds and related cost in profit or loss.
  - **Amendments to IAS 37**, "Provisions, contingent liabilities and contingent assets" specify which costs a company includes when assessing whether a contract will be loss-making.

Annual improvements make minor amendments to IFRS 1, "First - time Adoption of IFRS", IFRS 9, "Financial instruments", IAS 41, "Agriculture" and the Illustrative Examples accompanying IFRS 16, "Leases".

- Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 Interest Rate Benchmark Reform Phase 2; effective from Annual periods beginning on or after 1 January 2021. The Phase 2 amendments address issues that arise from the implementation of the reforms, including the replacement of one benchmark with an alternative one.
- Amendments to IFRS 17 and IFRS 4, 'Insurance contracts', deferral of IFRS 9; effective from annual periods beginning on or after 1 January 2021. These amendments defer the date of application of IFRS 17 by two years to 1 January 2023 and change the fixed date of the temporary exemption in IFRS 4 from applying IFRS 9, Financial Instrument until 1 January 2023.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

### NOTE 3 - RELATED PARTY DISCLOSURES

Transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note.

The details of short-term receivables and payables as of 31 March 2021 are as follows:

		<u>eivable</u> ırrent	<u>Payables</u> Current	
Shareholders	Trade	Non-trade	Trade	Non-trade
Muharrem Usta	-	43,117	-	50
Adem Elbaşı	-	1,446	-	-
	-	44,563	-	50
Other companies controlled by the shareholde	rs			
A ve A Sağlık A.Ş. (1)	6,276	-	4,145	_
Livart Tüp Bebek Özel Sağlık Hiz. A.Ş.	1,793	-	-	-
Konca Özel Sağlık Hizmetleri Ltd.Şti.	967	-	-	-
Miniso Mağazacılık A.Ş.	91	-	-	-
Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (2)	64	-	1,868	-
Pozitif Medikal Sistemler San. ve Tic. Ltd. Şti.	2	-	509	-
Saray Eczanesi	2	-	54	-
Samsunpark Özel Sağlık Tıbbı				
Malz. İnş. Tur. Tem. Tic. A.Ş. (3)	-	-	3,529	-
Cotyora Med. Özel Sağ. Taah. Hz.				
İnş. Tr. Loj. Ltd. Şti. (4)	-	-	1,970	-
Mp Sağlık ve Tic. A.Ş.	-	-	1,309	733
Tokat Emar Sağlık Hiz. Ltd. Şti.	-	-	449	-
Mt Sağlık Ürünleri San. ve Tic. A.Ş.	-	-	171	-
Diasan Basım ve Form Matbaacılık San. ve Tic.	A.Ş	-	15	-
Other	30	152	-	16
	9,225	152	14,019	749
	9,225	44,715	14,019	799

<sup>(1)</sup> A ve A Özel Sağ. Hiz. ve Cih. Teks. San. Tic. Ltd. Şti. provides cleaning materials for the hospitals.

<sup>(2)</sup> Fom Grup Mimarlık İnşaat ve Tic. A.Ş. provides turn key project management services for the furniture & fixture and leasehold improvements of the hospitals and audit of construction of the Group hospitals.

<sup>(3)</sup> Samsunpark Özel Sağlık Tıbbı Malz. İnş. Tur. Tem. Tic. A.Ş. provides cleaning, catering and laundry services for the Group

<sup>(4)</sup> Cotyora Med. Özel Sağ. Taah. Hz. İnş. Tr. Loj. Ltd. Şti. provides cleaning and catering services for the Group.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

### **NOTE 3 - RELATED PARTY DISCLOSURES (Continued)**

	31 December 2020			
	Recei	vables	Pay	ables
		ırrent		rrent
Shareholders	Trade	Non-trade	Trade	Non-trade
Muharrem Usta (*)	-	39,564	-	50
Adem Elbaşı	-	1,343	-	-
	-	40,907	-	50
Other companies controlled by the shareholders	<b>S</b>			
Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (1)	15,064	-	1,868	-
A ve A Sağlık A.Ş. (2)	8,309	=	9,125	-
Konca Özel Sağlık Hizmetleri Ltd.Şti.	208	=	-	-
Miniso Mağazacılık A.Ş.	42	=	-	-
Pozitif Medikal Sistemler San. ve Tic. Ltd. Şti.	2	-	509	-
Supra A.ŞSonotom Ltd Şti.				
-Ledmar Ltd Şti Mlp A.Ş. İş Ortaklığı	-	=	-	-
Cotyora Med. Özel Sağ. Taah. Hz.				
İnş. Tr. Loj. Ltd. Şti. (4)	-	=	1,407	-
Saray Eczanesi	-	=	216	-
Mp Sağlık ve Tic. A.Ş.	-	=	1,291	733
Mt Sağlık Ürünleri San. ve Tic. A.Ş.	-	=	116	-
Samsunpark Özel Sağlık Tıbbı Malz.				
İnş. Tur. Tem. Tic. A.Ş. (3)	=	-	3,146	-
Diasan Basım ve Form Matbaacılık San. ve Tic. A.Ş.	-	-	14	-
Tokat Emar Sağlık Hiz. Ltd. Şti.	-	-	514	-
Other	29	152	-	16
	23,654	152	18,206	749
	23,654	41,059	18,206	799

<sup>(\*)</sup> Non-trade receivables from Muharrem Usta is short term due date and interest charge from the current value of internal debt ratio of Group.

#### Advance given to related parties, prepaid expenses

	March 31, 2021	<b>December 31, 2020</b>
Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (1)	135,282	108,782
A ve A Sağlık A.Ş.	313	296
Sanport Gayrimenkul Geliştirme İnş.ve Tic.A.Ş	163	-
Atakum Özel Sağlık Hizmetleri İnş. Turizm ve San. Tic. A.Ş.	-	323
	135,759	109,401

<sup>(1)</sup> Fom Grup Mimarlık İnşaat ve Tic. A.Ş. provides turn key project management services for the furniture & fixture and leasehold improvements of the hospitals and audit of ongoing construction of the Group hospitals.

<sup>(2)</sup> A ve A Özel Sağ. Hiz. ve Cih. Teks. San. Tic. Ltd. Şti. provides cleaning materials for the hospitals.

<sup>(3)</sup> Samsunpark Özel Sağlık Tıbbı Malz. İnş. Tur. Tem. Tic. A.Ş. provides cleaning, catering and laundry services for the Group.

<sup>(4)</sup> Cotyora Med. Özel Sağ. Taah. Hz. İnş. Tr. Loj. Ltd. Şti. provides cleaning and catering services for the Group.

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

#### **NOTE 3 - RELATED PARTY DISCLOSURES (Continued)**

#### Fixed asset advances given to related parties

Thea asset advances given to related parties	March 31, 2021	<b>December 31, 2020</b>
Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (1)	136,015	124,364
Mp Sağlık ve Tic. A.Ş.	68,200	68,200
	204,215	192,564

<sup>(1)</sup> Fom Grup Mimarlık İnşaat ve Tic. A.Ş. provides turn key project management services for the furniture & fixture and leasehold improvements of the hospitals and audit of ongoing construction of the Group hospitals.

Related parties (sale and leaseback transactions)	March 31, 2021	<b>December 31, 2020</b>
Sancak Grup Mimarlık İnşaat ve Tic. A.Ş.		
(within non-current prepaid expenses)	2,614	2,811
Sancak Grup Mimarlık İnşaat ve Tic. A.Ş.		
(within prepaid expenses)	787	787
	2.404	2.500
	3,401	3,598

The balances above are resulting from sale and leaseback transactions of Efes Hospital (branch of Sentez Hospital) and Bahçelievler Hospital's land and buildings and are deferred under prepaid expenses and amortised in proportion to the lease payments over the period for which the asset is expected to be used since such losses are compensated for by future lease payments at below market price. Land of Efes Hospital was sold to Sancak Grup Mimarlık İnşaat ve Tic. A.Ş in 2010, resulting in a loss of TRY6,211, which was totally booked under the other current and non-current assets as of December 31, 2010 since the operational leasing agreement would become effective in 2011 and will be effective for 15 years. The building of Bahçelievler Hospital has been sold to Sancak Grup Mimarlık İnşaat ve Tic. A.Ş. in 2009, resulting in a loss of TRY5,591. The duration of leasing agreement of the building is 15 years starting from December, 2009. As at March 31, 2021, the Group has incurred rent expense amounting to TR197 due to amortization of prepaid rent (December 31, 2020: TRY787).

#### Lease liabilities from related parties

	March	31, 2021		December 31, 2020
	Current	Non-current	Current	Non-current
Sanport Gayrimenkul Gelistirme İns. ve Tic. A.S.	71,474	70.317	52,327	75,766
Fom Grup Mimarlık İnşaat ve Tic. A.Ş.	18,394	57,600	16,332	57,562
Gazi Medikal Sağlık Tesisleri ve Tic. A.Ş.	6,890	1,326	6,471	3,214
Atakum Özel Sağlik Hizmetleri İnş. Turizm ve San. Tic. A.Ş.	6,139	7,863	7,696	8,681
Özel Gebze Sentez Sağlık Hizmetleri ve Tic. A.Ş.	5,887	-	3,034	-
Tokat Medikal Grup Sağlık Turizm İnş. San. Tic. A.Ş.	1,980	651	2,268	1,011
Mp Sağlık ve Tic. A.Ş.	1,748	-	2,475	
	112,512	137,757	90,603	146,234
Purchases from related parties		January March 31, 2		January 1 - March 31, 2020
Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (2)(3)		6,	466	4,487
A ve A Özel Sağ. Hız. ve Cih. Teks. San. Tic. Ltd. Şti.	(1)	2,	721	3,654
		9,	187	8,141

- (1) Cleaning material purchases
- (2) Hospital rent expenses
- (3) Represents the paid rent expenses of the related period, evaluated within the scope of TFRS 16.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

### **NOTE 3 - RELATED PARTY DISCLOSURES (Continued)**

### **Operating expenses (including purchase of services)**

	January 1 -	January 1 -
	March 31, 2021	March 31, 2020
Sanport Gayrimenkul Geliştirme İnş. ve Tic. A.Ş. (1) (7)	27,908	24,967
Samsunpark Özel Sağ. Tıbbi Malz. İnş. Tur. Tem. Tic. A.Ş. (4)	5,615	4,161
Livart Tüp Bebek Özel Sağlık Hizm. A.Ş. (2)	5,599	1,917
Atakum Özel Sağlik Hiz. İnş. Turizm ve San. Tic. A.Ş. (1) (7)	3,617	2,820
Özel Gebze Sentez Sağlık Hizmetleri ve Tic. A.Ş. (1) (7)	2,130	1,891
Gazi Medikal Sağlık Tesisleri ve Tic. A.Ş. (1) (7)	2,010	1,844
Cotyora Med. Özel Sağ. Taah. Hz. İnş. Tr. Loj. Ltd. Şti. (4)	1,785	1,804
Mp Sağlık ve Tic. A.Ş. (1) (7)	1,913	1,684
Tokat Medikal Grup Sağlık Turizm İnş. San. Tic. A.Ş. (1)	868	700
Tokat Emar Sağlık Hiz. Ltd. Şti. (2) (5)	407	316
Saray Eczanesi (6)	228	194
Özdenler Sağ. Hiz. Dan. Turz. Gıd. San. Tic. Ltd. Şti. (2)	163	100
Mt Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (3)	58	64
Diasan Basım ve Form Matbaacılık San. ve Tic. A.Ş. (3)	-	11
	52,301	42,473

- (1) Hospital rent expenses
- (2) Doctor expenses
- (3) Stationary and consumable expenses
- (4) Cleaning, catering and laundry services
- (5) Medical equipment rent expenses
- (6) Drug purchase expenses
- (7) Represents the paid rent expenses of the related period, evaluated within the scope of TFRS 16.

Sales to related parties	January 1 - March 31, 2021	January 1 - March 31, 2020
A ve A Özel Sağ. Hız. ve Cih. Teks. San. Tic. Ltd. Şti. (1)	3,617	3,188
Adem Elbaşı	68	40
Samsunpark Özel Sağlık Tıbbi Malz. İnş. Turizm. Tem. Tic. A.Ş.	60	66
Miniso Mağazacılık A.Ş.	42	38
Cotyora Med.Özel Sağ.Taah. Hz. İnş. Tr. Loj. Ltd. Şti.	22	33
Tokat Medikal Grup Sağlık Turizm İnş. San. Tic. A.Ş.	22	-
Saray Eczanesi	1	3
Fom Grup Mimarlık İnşaat ve Tic. A.Ş.	-	2
	3,832	3,370
(1) Outsourcing laboratory services		
(2) Imaging services		
Interest income from related parties	January 1 - March 31, 2021	January 1 - March 31, 2020
Muharrem Usta	2,014	1,169
	2,014	1,169

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

### **NOTE 3 - RELATED PARTY DISCLOSURES (Continued)**

### Compensation of key management personnel:

Key management personnel comprise general managers, deputy general managers and chief physicians of hospitals and head office management team.

The remuneration of directors and other members of key management during the year were as follows:

	January 1 - March 31, 2021	January 1 - March 31, 2020
Salaries and other short-term benefits	5,264	4,924
	5,264	4,924

### NOTE 4 - CASH AND CASH EQUIVALENTS

	March 31, 2021	<b>December 31, 2020</b>
Cash on hand	30,230	26,746
Cash at banks	534,919	338,224
Other cash equivalents (*)	14,098	10,027
	579,247	374,997

<sup>(\*)</sup> Other cash equivalents consist of credit card receivables from banks.

### **NOTE 5 - FINANCIAL INSTRUMENTS**

### **Financial Liabilities**

### **Bank Loans and Bonds**

	March 31, 2021	<b>December 31, 2020</b>
Short-term bank borrowings	31,250	41,223
Short-term bonds issued	384,609	322,520
Current portion of long term borrowings	374,110	348,666
Current portion of long-term bank loans	374,110	348,666
Interest expense accruals	66,272	43,819
	856,241	756,228
Long-term bank loans	891,766	944,203
Issued bonds	70,000	
	961,766	944,203
Total borrowings	1,818,007	1,700,431

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

### **NOTE 5 - FINANCIAL INSTRUMENTS (Continued)**

The reconciliation of the liabilities arising from financing activities as of 1 January- 31 March 2021 and 1 January- 31 December 2020 are as follows:

1	January 2021	Financing cash flows	Foreign exchange effect (Note 21)	Disposal of subsidiary	Other (*)	March 31, 2021
Bank loans	1,700,431	127,636	(10,060)	_	_	1,818,007
Finance lease obligations	196,064	(24,857)	13,119	_	_	184,326
Lease obligations	595,102	(75,281)	6,039	-	101,469	627,329
	2,491,597	27,498	9,098	-	101,469	2,629,662
1	January 2020	Financing cash flows	Foreign exchange effect (Note 21)	Disposal of subsidiary	Other (*)	March 31, 2020
1 Bank loans	•	cash flows	exchange effect (Note 21)	-	Other (*)	2020
Bank loans	January 2020 1,534,863 211,880	0	exchange effect	-	Other (*)	2020 1,658,128
	1,534,863	cash flows	exchange effect (Note 21)	-	Other (*)	,

<sup>(\*)</sup> Some of the lease obligations within the scope of TFRS 16 are due to the re-measurement of the reduced lease obligations and interest expenses due to the change in the lease payments realized within the period.

As of March 31, 2021 and December 31, 2020 the repayment schedule of the total borrowings as follows:

|--|

11410101, 2021	Weighted Average			
<b>Currency Type</b>	Effective Interest Rate	Current	Non-current	Total
TRY	19,52%	365,256	47,495	412,751
TRY TLRef	£+4%-TRLibor+3.50%-5.80%-DIBS+5.50%	311,365	914,271	1,225,636
Euro	Euribor + 5.50%	179,620	<u> </u>	179,620
		856,241	961,766	1,818,007
December 31, 2020				
December 01, 2020	Weighted Average			
<b>Currency Type</b>	Effective Interest Rate	Current	Non-current	Total
TRY	18%	447,991	57,770	505,761
TRY	TRLibor +3.50% - 4.00% - 4.50% - 5.80	142,865	472,148	615,013
EUR	Euribor + 5.50%	165,372	414,285	579,657
		756,228	944,203	1,700,431

As of March 31, 2021, there are no blocked cash accounts related to the group's loans (December 31, 2020: None).

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

### **NOTE 5 - FINANCIAL INSTRUMENTS (Continued)**

As at March 31, 2021 and December 31, 2020 the repayment schedule of the borrowings in TRY are as follows:

	March 31, 2021	<b>December 31, 2020</b>
Interest expense accruals	66,272	43,819
To be paid within 1 year (*)	789,969	712,409
To be paid between 1-2 years	504,170	381,087
To be paid between 2-3 years	347,557	315,170
To be paid between 3-4 years	73,159	174,021
To be paid between 4-5 years	36,880	73,925
	1,818,007	1,700,431

<sup>(\*)</sup> TRY31,250 of the loans to be paid within one year consists of revolving loans and TRY384,609 part consists of bond payments which will be redeemed within 1 year.

#### Covenants:

The Company has a structured finance facility in place. A syndicate loan agreement was signed on December 31, 2015 with seven banks including Türkiye İş Bankası A.Ş., Türkiye Garanti Bankası A.Ş., Denizbank A.Ş., Denizbank A.Ş., Denizbank A.Ş., ING European Financial Services PLC and ING Bank A.Ş. The withdrawal of the syndicate loan took place in February 2016. As a guarantee for the syndicate loan used, there is a pledge over all of shares of MLP, and shares in subsidiaries owned by MLP and all fixed assets under ownership of MLP and the MLP's bank accounts. In addition to this, the loan is secured via assignment of MLP's receivables arising from various agreements including medical tourism agreements and insurance policies.

The syndicate loan includes a number of financial covenants stated below:

The Debt Service Coverage Ratio ("DSCR") cannot be below 1.1 during the term of the agreement (2016-2024). DSCR is tested every six months starting from December 31, 2016.

Net debt to EBITDA Ratio cannot be above x4.0 for the year ended December 31, 2016 and for the six months period ended June 30, 2017, x3.5 for the year ended December 31, 2017 and for the six months period ended June 30, 2018, x3.0 for the year ended December 31, 2018 and for the six months period ended June 30, 2019 and x2.5 for the remaining period of the syndicate loan.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

## **NOTE 5 - FINANCIAL INSTRUMENTS (Continued)**

### **Lease Obligations**

The Group has the following finance lease obligations which arose mainly due to lease of medical machinery and equipment:

	Minimum le	Minimum lease payments		Present value of minimum lease payments	
Obligations under finance leases	March 31, 2021	December 31, 2020	March 31, 2021	December 31, 2020	
Within one year In the second to fifth years inclusive	117,129 80,420	113,476 98,260	107,669 76,657	102,825 93,239	
	197,549	211,736	184,326	196,064	
Less : Future finance charges	(13,223)	(15,672)	-	<u>-</u>	
Present value of finance lease obligations	184,326	196,064	184,326	196,064	
Less: Amounts due to settlement within twelve months (shown under current liabilities)	107,669	102,825	107,669	102,825	
Present value of finance lease obligations	76,657	93,239	76,657	93,239	
Liabilities arising from lease transactions		March	31, 2021	December 31, 2020	
Within one year More than one year			119,705 507,624	118,792 476,310	
Present value of finance lease obligations			627,329	595,102	

#### NOTE 6 - TRADE RECEIVABLES AND PAYABLES

### **Trade Receivables**

Current trade receivables	March 31, 2021	<b>December 31, 2020</b>
Trade receivables	960,279	932,886
Income accruals from continuing treatments	230,778	162,290
Other trade income accruals	20,942	35,699
Trade receivables from related parties (Note 3)	9,225	23,654
Notes receivables	12,440	17,283
Allowance for doubtful receivables (-)	(16,954)	(16,696)
	1,216,710	1,155,116

Trade receivables due from the SSI constitute 41% (December 31, 2020: 43%) and receivables due from foreign patients constitute 22% (December 31, 2020: 21%) of total trade receivables.

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

## NOTE 6 - TRADE RECEIVABLES AND PAYABLES (Continued)

#### **Trade Receivables (Continued)**

Deposits given

The Group has trade receivables arising from health services given to foreign patients amounting to TRY214,576 as at March 31, 2021. These receivables have a longer maturity and higher profitability compared to other institutions that the Group works such as SSI and private insurance companies. Collections of these receivables are followed up regularly by the Group. The Group has receivables from the Government of Libya amounting to TRY136,949 as of 31 March 2021.

Allowance for doubtful receivables for the trade receivables is determined depending on past experiences of irrecoverable amounts.

As of March 31, 2021, trade receivables of an initial value of TRY 16,954 (December 31, 2020: TRY16,696) were fully impaired and fully provided for. No collaterals are received in relation to these trade receivables.

#### Movement of allowance for doubtful receivables

	January 1 - March 31, 2021	January 1 - March 31, 2020
Balance at beginning of the period	16,696	13,929
Charge for the period	274	596
Collections	(16)	(529)
Balance at closing of the period	16,954	13,996
Trade Payables		
Short term trade payables	March 31, 2021	<b>December 31, 2020</b>
Trade payables	817,687	756,834
Trade payables due to related parties (Note 3)	14,019	18,206
Other expense accruals	242,898	210,452
Other trade payables	1,906	1,638
	1,076,510	987,130
NOTE 7 - OTHER RECEIVABLES AND PAYABLES		
Other Receivables		
Other current receivables	March 31, 2021	<b>December 31, 2020</b>
Non-trading receivables due from related parties (Note 3)	44,715	41,059
Receivables from tax office	9,106	10,983
Deposits given	4,657	4,449
Other miscellaneous receivables	19,445	27,876
	77,923	84,367
Other non-current receivables	March 31, 2021	December 31, 2020

2,805

2,805

2,740

2,740

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

<b>NOTE 7 - OTHER</b>	RECEIVABLES	AND PAYABLES	(Continued)
NOIE / - OTHER	RECEIVABLES.	AND FATABLES	Comuniueaz

Other current payables	March 31, 2021	<b>December 31, 2020</b>
Payables relating to business combinations	29,245	29,068
Other taxes and funds payable	25,821	19,916
Non-trading payables due to related parties (Note 3)	799	799
Other miscellaneous payables	1,728	1,901
	57,593	51,684
Other non-current payables	March 31, 2021	<b>December 31, 2020</b>
Payables relating to business combinations	103,317	106,471
	103,317	106,471

### **NOTE 8 - INVENTORIES**

Inventories	March 31, 2021	<b>December 31, 2020</b>
Pharmaceutical inventory	48,854	44,779
Laboratory inventory	33,689	37,395
Medical consumables inventory	25,570	29,668
Other inventory	869	1,640
	108 982	113 482

### NOTE 9 - PREPAID EXPENSES AND DEFERRED INCOME

## **Prepaid Expenses**

Short term prepaid expenses	March 31, 2021	<b>December 31, 2020</b>
Order advances	443,214	366,738
Prepaid insurance expenses	14,283	19,069
Prepaid rent expenses	12,845	16,759
Prepaid sponsorship expenses	3,021	2,586
Other	5,616	9,111
	478,979	414,263
Long term prepaid expenses	March 31, 2021	December 31, 2020
	March 31, 2021 292,529	December 31, 2020 277,231
Long term prepaid expenses  Fixed asset advances given Prepaid rent expenses	,	,
Fixed asset advances given	292,529	277,231

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

## NOTE 9 - PREPAID EXPENSES AND DEFERRED INCOME (Continued)

### **Deferred Income**

Short term accrued income	March 31, 2021	December 31, 2020
Advances received	256,411	217,754
Deferred revenue	2,986	3,743
	259,397	221,497
Long term accrued income	March 31, 2021	<b>December 31, 2020</b>
Deferred revenue	2,122	2,211
	2,122	2,211

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

### NOTE 10 - ROPERTY, EQUIPMENT AND OTHER INTANGIBLE ASSETS

Cost	M Buildings	achinery and equipment	Vehicles	Furniture and fixture	Leased assets	Leasehold improvements	Construction in	Total
Cost	Dullulings	equipment	venicles	HATUIE	assets	improvements	progress	Total
Opening balance as of January 1, 2021	817	753,417	1,546	361,807	371,073	601,052	65,220	2,154,932
Additions	-	10,492	80	8,463	-	11,300	10,026	40,361
Disposals	_	(15)	_	(53)	-	(305)	-	(373)
Transfers	-	22,253	-	10,443	(4,058)	-	(28,638)	<u> </u>
Closing balance as of March 31, 2021	817	786,147	1,626	380,660	367,015	612,047	46,608	2,194,920
Accumulated depreciation								_
Opening balance as of January 1, 2021	(96)	(527,196)	(1,550)	(241,003)	(322,872)	(297,970)	-	(1,390,687)
Charge for the period (*)	(4)	(19,278)	(19)	(7,936)	(5,319)	(10,548)	-	(43,104)
Disposals	-	15	· -	39	-	279	-	333
Transfers	-	-	-	-	-	-	-	
Closing balance as of March 31, 2021	(100)	(546,459)	(1,569)	(248,900)	(328,191)	(308,239)	-	(1,433,458)
Carrying value as of March 31, 2021	717	239,688	57	131,760	38,824	303,808	46,608	761,462

<sup>(\*)</sup> Depreciation and amortization expense of TRY41,022 (January 1 - March 31, 2020: TRY41,488) has been charged in 'cost of service', TRY4,445 (January 1-March 31, 2020: TRY3,444) has been charged in 'operating expenses' for the period ended between January 1- March 31, 2021.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

## NOTE 10 - PROPERTY, EQUIPMENT AND OTHER INTANGIBLE ASSETS (Continued)

		<b>lachinery</b> and	¥7 1 • 1	Furniture and	Leased	Leasehold	Construction in	TD 4.1
Cost	Buildings	equipment	Vehicles	fixture	assets	improvements	progress	Total
Opening balance as of January 1, 2020	1,266	660,171	1,546	311,064	391,443	552,043	90,101	2,007,634
Additions	_	2,621	79	7,351	_	10,029	6,198	26,278
Assets acquired by business combinations (Note 26	) -	16,771	-	· -	_	, <u>-</u>	, <u>-</u>	16,771
Disposals	(226)	(113)	(80)	(74)	-	(18)	-	(511)
Transfers	-	49,528	-	23,607	(8,216)	-	(64,919)	
Closing balance as of March 31, 2020	1,040	728,978	1,545	341,948	383,227	562,054	31,380	2,050,172
Accumulated depreciation								
Opening balance as of January 1, 2020	(80)	(454,298)	(1,546)	(200,756)	(316,292)	(258,916)	-	(1,231,888)
Charge for the period	(4)	(16,417)	(21)	(9,497)	(7,364)	(9,325)	-	(42,628)
Disposals	9	-	80	9	-	8	-	106
Transfers	-	(5,290)	-	(2,827)	8,117		-	
Closing balance as of March 31, 2020	(75)	(476,005)	(1,487)	(213,071)	(315,539)	(268,233)	-	(1,274,410)
Carrying value as of March 31, 2020	965	252,973	58	128,877	67,688	293,821	31,380	775,762

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

## NOTE 10 - PROPERTY, EQUIPMENT AND OTHER INTANGIBLE ASSETS (Continued)

Cost	Licenses	Rights	Other	Total
Opening balance as of January 1, 2021	596,072	82,384	3,245	681,701
Additions Transfers	- -	3,098	- -	3,098
Closing balance as of March 31, 2021	596,072	85,482	3,245	684,799
Accumulated amortization				
Opening balance as of January 1, 2021	-	(42,629)	(884)	(43,513)
Charge for the period	-	(2,293)	(70)	(2,363)
Closing balance as of March 31, 2021	-	(44,922)	(954)	(45,876)
Carrying value as of March 31, 2021	596,072	40,560	2,291	638,923
Cost	Licenses	Rights	Other	Total
Opening balance as of January 1, 2020	477,982	64,449	3,224	545,655
Assets acquired by business combinations (Note 26) Additions Transfers	118,090 - -	9,742 -	21	118,090 9,763
Closing balance as of March 31, 2020	596,072	74,191	3,245	673,508
Accumulated amortization				
Opening balance as of January 1, 2020	-	(33,790)	(605)	(34,395)
Charge for the period	-	(2,235)	(69)	(2,304)
Closing balance as of March 31, 2020	-	(36,025)	(674)	(36,699)
Carrying value as of March 31, 2020	596,072	38,166	2,571	636,809

## NOTE 11 - RIGHT OF USED ASSETS

	Hospital Buildings	Total	
Opening balance as of January 1, 2021	257,440	257,440	
Additions Charge for the year (*)	65,549 (27,388)	65,549 (27,388)	
Closing balance as of March 31, 2021	295,601	295,601	

<sup>(\*)</sup> For the period ended March 31, 2021, right of use assets depreciation expenses of TRY 26,962 has been charged to 'cost of service' (1 January – 31 March 2020: TRY17,176), TRY 426 to 'general administrative and marketing expenses (1 January – 31 March 2020: TRY366).

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021 (Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 11 - RIGHT OF USE ASSETS (Continued)		
	Hospital Buildings	Total
Opening balance as of January 1, 2020	235,087	235,087
Additions Charge for the year	73,512 (17,542)	73,512 (17,542
Closing balance as of March 31, 2020	291,057	291,057
NOTE 12 - PAYABLES FOR EMPLOYEE BENEFITS		
Payables for employment benefits:	March 31, 2021	December 31, 2020
Fees payable to doctors and other personnel Social security premiums payable	81,035 15,779	76,191 15,188
	96,814	91,379
Short term provision for employment benefits:	March 31, 2021	December 31, 2020
Unused vacation provision	21,758	19,090
	21,758	19,090
Long term provision for employment benefits:	March 31, 2021	December 31, 2020
Retirement pay provision Unused vacation provision	19,803 10,719	21,311 8,896
	30,522	30,207
NOTE 13 - OTHER ASSETS AND LIABILITIES		
Other current assets:	March 31, 2021	December 31, 2020
VAT carried forward Other miscellaneous current assets	40,865 5,317	38,408 4,645
	46,182	43,053
NOTE 14 - PROVISIONS		
Other short-term provisions:	March 31, 2021	December 31, 2020
Litigation provisions	19,293	13,733
Social Security discounts provisions	5,775	6,634

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

### **NOTE 15 - COMMITMENTS**

March 31, 2021	Total	TRY	USD	EUR
<b>A.</b> CPM given on behalf of its own legal entity	75,449	70,808	156	342
-Collateral	75,449	70,808	156	342
-Pledge	-	-	-	-
-Mortgage	-	-	-	-
<b>B.</b> CPM given on behalf of the subsidiaries included in	l			
full consolidation (*)	62,013	59,406	-	267
-Collateral	62,013	59,406	-	267
-Pledge	-	-	-	-
-Mortgage	-	-	-	-
C. CPM given for execution of ordinary				
commercial activities to collect third parties debt	-	-	-	-
-Collateral	-	-	-	-
-Pledge	-	-	-	-
-Mortgage	-	-	-	-
<ul><li>D. Total amount of other CPM given</li><li>i. Total Amount of CPM on behalf of the</li></ul>				
main partner	-	-	-	-
-Collateral	-	-	-	-
-Pledge	-	-	-	-
-Mortgage	-	-	-	-
ii. Total amount of CPM given on behalf of other				
Company companies that do not cover B and C	-	-	_	_
-Collateral	-	-	-	-
-Pledge	-	-	-	-
-Mortgage	-	-	-	-
iii. Total amount of CPM on behalf of third parties the do not cover C.	at -	_	_	_
-Collateral	_	-	_	_
-Pledge	-	-	-	_
-Mortgage	-	-	-	-
TOTAL	137,462	130,214	156	609

<sup>(\*)</sup> The Group has given guarantees amounting to TRY 67,908 related to the loans in Note 5 for the companies under full consolidation.

Guarantees given generally include letters of guarantee received from banks to be given to institutions and suppliers in order to participate in government tenders.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

## **NOTE 15 - COMMITMENTS (Continued)**

31 December 2020	Total TRY Equivalent	TRY	USD	EUR
A.CPM given on behalf of its own legal entity	71,194	66,968	156	342
- Collateral	71,194	66,968	156	342
- Pledge - Mortgage	-	-	-	-
B. CPM given on behalf of the subsidiaries				
included in full consolidation (*)	58,959	56,555	-	267
- Collateral	58,959	56,555	-	267
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
C. CPM given for execution of ordinary				
commercial activities to collect third parties debt	-	-	-	-
- Collateral	-	-	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
D. Total amount of other CPM given				
i. Total Amount of CPM on behalf of the main partner	-	-	-	-
- Collateral	-	-	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
ii. Total amount of CPM given on behalf of other				
Company companies that do not cover B and C	-	-	-	-
- Collateral	-	-	-	-
- Pledge	-	-	-	-
- Mortgage	-	=	-	-
iii. Total amount of CPM on behalf of third				
parties that do not cover C.	-	-	-	-
- Collateral	-	-	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	
Total	130,153	123,523	156	609

<sup>(\*)</sup> The Group has given guarantees amounting to TRY64,991 related to the loans in Note 5 for the companies under full consolidation.

Guarantees given generally include letters of guarantee received from banks to be given to institutions and suppliers in order to participate in government tenders.

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

#### NOTE 16 - SHARE CAPITAL/OTHER RESERVES

Shareholders	(%)	March 31, 2021	(%)	December 31, 2020
Lightyear Healthcare B.V.	30.69	63,844	30.69	63,844
Sancak İnşaat Turizm Nakliyat ve Dış Ticaret A.Ş.	15.35	31,943	15.35	31,943
Muharrem Usta	8.98	18,678	8.98	18,678
Hujori Financieringen B.V.	3.98	8,287	3.98	8,287
Adem Elbaşı	2.99	6,226	2.99	6,226
İzzet Usta	1.20	2,490	1.20	2,490
Saliha Usta	0.90	1,868	0.90	1,868
Nurgül Dürüstkan Elbaşı	0.90	1,868	0.90	1,868
Publicly Traded (*)	35.01	72,833	35.01	72,833
Nominal capital	100.00	208,037	100.00	208,037

(\*) The shareholders of the Company purchased 6,827 thousand shares from the publicy traded portion of the capital. Distribution of the shares purchased is as follows; 3,224 thousand shares representing 4.43% of the publicly traded portion were purchased by Lightyear Healthcare B.V., 1,613 thousand shares representing 2.21% of the publicly traded portion of the capital were purchased by Sancak İnşaat, 943 thousand shares representing 1.29% of the publicly traded portion of the capital were purchased by Muharrem Usta, 418 thousand shares representing 0.57% of the publicly traded portion of the capital were purchased by Hujori Financieringen B.V., 314 thousand shares representing 0.43% of the publicly traded portion of the capital were purchased by Adem Elbaşı and lastly other shareholders purchased 314 shares representing 0.43% of the publicly traded portion. 1,613 thousand shares purchased by Sancak İnşaat from the publicy traded portion were sold on September 24, 2018. 126 thousand shares purchased by İzzet Usta and 18 thousand shares purchased by Adem Elbaşı from the publicy traded portion were sold.

As of March 31, 2021 the total number of ordinary shares is 208,037 thousand shares (2020: 208,037 thousand shares) with a par value of TRY1 per share (2020: TRY1 per share).

The share capital is divided into 208,037 thousand shares (December 31, 2020: 208,037 thousand shares), with 88,229 thousand A type shares and 119,808 thousand B type shares.

In accordance with the Capital Markets Board's (the "CMB") Resolution No: 21/655 issued on July 23, 2010, it is regarded that 33.36% of the shares are in circulation in accordance with CSD as of March 31, 2021 (Note 1). Shares in circulation rate is 33.36% as of April 3, 2021.

### **Share premiums:**

	March 31, 2021	<b>December 31, 2020</b>
Share Premiums	556,162	556,162
	556,162	556,162

On February 7, 2018, the Group launched initial public offering ("IPO") of 72,834 thousand B type bearer shares corresponding to 35.01% of total shares. From the initial public offering, TRY600,000 was generated to the Group. After the IPO related expenses amounting to TRY12,259 were deducted from proceeds, out of TRY587,741, share capital increase was made with the amount of TRY31,579 and the remaning amount was used in the share premium increase by TRY556,162.

#### Reserves:

	March 31, 2021	<b>December 31, 2020</b>
Legal reserves	302	302
Restricted reserves appropriated from profit	9,958	9,958
Revaluation reserves	37,747	37,747
	48,007	48,007

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

### NOTE 16 - SHARE CAPITAL/OTHER RESERVES (Continued)

#### Legal reserves

The legal reserves consist of first and second legal reserves, appropriated in accordance with the Turkish Commercial Code. The first legal reserve is appropriated out of historical statutory profits at the rate of 5% per annum, until the total reserve reaches 20% of the historical paid-in share capital. The second legal reserve is appropriated after the first legal reserve and dividends, at the rate of 10% per annum of all cash dividend distributions.

#### NOTE 17 - REVENUE AND COST OF SERVICES

Revenue	January 1 - March 31, 2021	January 1 - March 31, 2020
Hospital services (*)	1,211,304	978,870
	1,211,304	978,870

(\*) Hospital services includes foreign medical revenue and other income.

Cost of services	January 1 - March 31, 2021	January 1 - March 31, 2020
Doctor expenses	(262,670)	(203,652)
Material consumption	(241,393)	(211,486)
Personnel expenses	(160,549)	(145,015)
Services rendered by third parties	(100,317)	(68,496)
Depreciation and amortization expenses (Note 10,11)	(67,984)	(58,664)
Rent expenses (Hospitals)	(8,930)	(6,753)
Other (*)	(66,413)	(55,960)
	(908,256)	(750,026)

<sup>(\*)</sup> Other expenses mainly comprise expenses incurred for electricity, water and natural gas.

### **NOTE 18 - OPERATING EXPENSES**

General administrative and marketing expenses	January 1 - March 31, 2021	January 1 - March 31, 2020
Personnel expenses	(35,539)	(32,684)
Sponsorship and advertising expenses (*)	(25,454)	(24,691)
Depreciation and amortization expenses (Note 10,11)	(4,871)	(3,810)
Outsourcing expenses	(3,258)	(2,490)
Rent Expenses	(2,102)	(2,150)
Communication expenses	(1,600)	(626)
Representation and entertainment expenses	(937)	(581)
Maintenance and repair expenses	(785)	(625)
Taxes and duties	(761)	(1,481)
Bad debt allowance	(274)	(596)
Utility expenses	(266)	(434)
Other	(8,927)	(3,808)
	(84,774)	(73,976)

<sup>(\*)</sup> Sponsorship and advertising expenses includes marketing expenses related to the income of domestic and foreing medical tourism.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

## NOTE 19 - OTHER INCOME AND EXPENSES FROM OPERATING ACTIVITIES

Other income from operating activities	January 1 - March 31, 2021	January 1 - March 31, 2020
Foreign exchange gains from operations	73,552	73,370
Interest income	4,517	5,139
Trade payables discount	2,236	(1,239)
Collection of doubtful receivables (Note 6)	16	529
Other income	4,534	4,420
	84,855	82,219
Other expenses from operating activities	January 1 - March 31, 2021	January 1 - March 31, 2020
Foreign exchange losses from operations	(40,664)	(56,269)
Biomedical equipment damage	(2,973)	· -
SSI return expenses	(2,414)	(1,626)
Non-operational hospital expenses	(1,450)	(798)
Trade receivables discount	(783)	583
Other expenses	(8,745)	(9,218)
	(57,029)	(67,328)

### NOTE 20 - INCOME AND EXPENSES FROM INVESTING ACTIVITIES

Income from investing activities	January 1 - March 31, 2021	January 1 - March 31, 2020
Gain on sale of fixed assets	234	482
Gain on bargain purchase (Note 26)		81,980
	234	82,462
Expense from investing activities	January 1 - March 31, 2021	January 1 - March 31, 2020
Loss on sale of fixed assets	(2)	(98)
	(2)	(98)

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021 (Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 21 - FINANCE EXPENSES	January 1 -	January 1 -
Finance expenses (-)	March 31, 2021	March 31, 2020
Interest expenses from bank borrowings	(41,603)	(46,982
Interest expenses from lease liabilities	(35,920)	(36,739
Interest expenses from bonds issued	(25,920)	(10,209
Bank commissions	(6,372)	(6,061
Interest expenses from financial lease obligations	(3,309)	(3,999
Other interest expenses	(9,384)	(4,459
Total interest expenses	(122,508)	(108,449
Fair value differences of derivative financial instruments (net)-	(6,039)	(4,912
Net foreign exchange loss	(3,059)	(63,532
Net foreign exchange loss from lease liabilities (Note 5)	<u> </u>	11,287
	(131,606)	(165,606
NOTE 22 - TAXES ON INCOME (DEFERRED TAX ASSET A		ŕ
NOTE 22 - TAXES ON INCOME (DEFERRED TAX ASSET A	ND LIABILITIES IN March 31, 2021	ŕ
· ·		<b>December 31, 2020</b>
Short term payables due to current tax	March 31, 2021	December 31, 2020
Short term payables due to current tax	March 31, 2021 12,932	December 31, 2020 17,708
Short term payables due to current tax  Current period tax liabilities  Current tax liabilities	March 31, 2021  12,932  12,932  March 31, 2021	17,708 17,708 December 31, 2020
Short term payables due to current tax  Current period tax liabilities  Current tax liabilities  Current corporate tax provision	March 31, 2021 12,932 12,932	December 31, 2020  17,708  17,708  December 31, 2020  34,119
Short term payables due to current tax  Current period tax liabilities  Current tax liabilities	March 31, 2021  12,932  12,932  March 31, 2021	December 31, 2020  17,708  17,708  December 31, 2020  34,119
Short term payables due to current tax  Current period tax liabilities  Current tax liabilities  Current corporate tax provision	March 31, 2021  12,932  12,932  March 31, 2021	17,708 17,708 17,708 December 31, 2020 34,119 (16,411)
Short term payables due to current tax  Current period tax liabilities  Current tax liabilities  Current corporate tax provision	March 31, 2021  12,932  12,932  March 31, 2021  12,932  12,932  January 1 -	December 31, 2020  17,708  17,708  December 31, 2020  34,119 (16,411)  17,708
Short term payables due to current tax  Current period tax liabilities  Current tax liabilities  Current corporate tax provision	March 31, 2021  12,932  12,932  March 31, 2021  12,932  12,932	December 31, 2020  17,708  17,708  December 31, 2020  34,119 (16,411)  17,708  January 1
Short term payables due to current tax  Current period tax liabilities  Current tax liabilities  Current corporate tax provision Less: Prepaid taxes and funds	March 31, 2021  12,932  12,932  March 31, 2021  12,932  12,932  January 1 -	December 31, 2020  17,708  17,708  17,708  December 31, 2020  34,119 (16,411)  17,708  January 1- March 31, 2020  (4,133

(34,845)

(25,147)

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

## NOTE 22 - TAXES ON INCOME (DEFERRED TAX ASSET AND LIABILITIES INCLUDED) (Continued)

#### Corporate Tax

The Group is subject to Turkish corporate tax. Provision is made in the accompanying consolidated financial statements for the estimated charge based on the Group's results for the years and periods. Turkish tax legislation does not permit a parent company and its subsidiary to file a consolidated tax return. Therefore, provisions for taxes, as reflected in the consolidated financial statements, have been calculated on a separate-entity basis.

Corporate tax is applied on taxable corporate income, which is calculated from the statutory accounting profit by adding back non-deductible expenses, and by deducting dividends received from resident companies, other exempt income and investment incentives utilized.

In accordance with the regulation numbered 7316, published in Official Gazette on 22 April 2021, "Law on the Amending the Procedure Law on Collection of Public Claims and Some Other Laws", in temporary declarations to be issued after 01.07.2021, the corporate tax rate has increased from 20% to 25% and to 23% for 2022.

In Turkey, advance tax returns are filed on a quarterly basis. Advance corporate income tax rate applied in 2021 is 20% (2020: 22%). Losses are allowed to be carried 5 years maximum to be deducted from the taxable profit of the following years. However, losses incurred cannot be deducted from the prior years' profit retrospectively.

In Turkey, there is no procedure for a final and definitive agreement on tax assessments. Companies file their tax returns between 1-25 April following the close of the accounting year to which they relate. Tax authorities may, however, examine such returns and the underlying accounting records and may revise assessments within five years

#### Deferred Tax

The Group recognizes deferred tax assets and liabilities based upon temporary differences arising between its financial statements as reported for IFRS purposes and its statutory tax financial statements. These differences usually result in the recognition of revenue and expenses in different reporting periods for IFRS and tax purposes and they are given below. Tax rate used in the calculation of deferred tax assets and liabilities was 22% over temporary timing differences expected to be reversed in 2018, 2019 and 2020, and 20% over temporary timing differences expected to be reversed in 2021 and the following years (2020: 22%).

In Turkey, the companies cannot declare a consolidated tax return, therefore subsidiaries that have deferred tax assets position were not netted off against subsidiaries that have deferred tax liabilities position and disclosed separately.

#### Investment Incentive Certificate

The Group has various investment incentive certificates that were signed by the Turkish Ministry of Economy and approved by General Directorate of Incentive Implementation and Foreign Capital. With those incentives, the Group is eligible for a corporate tax deduction rate ranging between 40%- 80% for an unlimited time, which amounts to a total deferred tax asset of TRY173,017 (December 31, 2020: TRY160,332). Respective deferred tax asset was calculated to be 15%- 40% of total investment contribution with regards to the respective investment incentive certificates. Additionally, the Group is entitled to social security premium support from the Turkish Ministry of Economy, related to the hospitals that have completed their greenfield investments.

As of March 31, 2021, the Group has tax loss amounting to TRY316,507 (December 31, 2020: TRY426,574). TRY63,302 (December 31, 2020: TRY85,316) deferred tax assets have been recorded concerning this loss.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

## NOTE 22 - TAXES ON INCOME (DEFERRED TAX ASSET AND LIABILITIES INCLUDED) (Continued)

Deferred tax assets/(liabilities):	March 31, 2021	<b>December 31, 2020</b>
Tax losses carried forward	63,302	85,316
Depreciation differences of tangible and intangible assets	(174,335)	(174,096)
Provision for employment termination benefits	3,961	4,262
Vacation pay liability	6,495	5,597
Temporary difference between the tax base and	-,	7
carrying amount of financial liabilities	(3,936)	(3,778)
Prepaid building expenses	(2,662)	(3,033)
Tax advantage from investment incentive	173,017	160,332
Right of use asset	66,346	67,532
Other	63,215	75,747
	195,403	217,879
Deferred tax asset	378,853	401,531
Deferred tax liability	(183,450)	(183,652)
	195,403	217,879
Tax losses carried forward and their expiry dates are as follows:	March 31, 2021	
	Water 51, 2021	
	Losses carried	Losses carried
	forward for	forward for
	which deferred	which deferred tax
Expiration schedule of carryforward tax losses	tax assets recognized	assets not recognized
Expiring in 2022	59,294	_
Expiring in 2023	118,385	_
Expiring in 2024	64,310	_
Expiring in 2025	55,608	<u>-</u>
Expiring in 2026	18,910	_
Expring in 2020	10,710	
	316,507	<u> </u>
	December 31, 202	20
	Losses carried	Losses caried
	forward for which	forward for which
	deferred tax	deferred tax
Expiration schedule of carryforward tax losses	assets recognized	assets not recognized
<u> </u>		
Expiring in 2020	-	-
Expiring in 2021	43,063	-
Expiring in 2022	142,458	-
Expiring in 2023	120,453	-
Expiring in 2024	64,998	-
Expiring in 2025	55,602	<u>-</u>
	426,574	_
	,	

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

## NOTE 22 - TAXES ON INCOME (DEFERRED TAX ASSET AND LIABILITIES INCLUDED) (Continued)

Movement of deferred tax (assets)/liabilities for the period ended March 31, 2021 and March 31, 2020 are as follows:

Movement of deferred tax liabilities:	January 1 - March 31, 2021	January 1 - March 31, 2020 (243,138)	
Opening balance as at January 1	(217,879)		
Charged to profit or loss	21,913	21,014	
Charged to equity	563	(47)	
Closing balance as at year end	(195,403)	(222,171)	

The reconciliation of the current tax expense and net income for the period is as follows:

Reconcilation of tax provision:	January 1 - March 31, 2021	January 1 - March 31, 2020
Loss before tax	114,726	86,517
Tax at the domestic income tax rate of 20% (2020: 22%)	(22,945)	(19,034)
Tax effects of:		
- Expenses that are not deductible in	(6,074)	(13,878)
- Effect of tax advantage from investment incentive	12,685	1,702
- Tax losses carried forward not subject to deferred tax	(22,151)	(587)
- Change in income tax rate from 20% to 22%	· · · · · ·	7,609
- Reduced corporate tax effect	3,315	33
- Other	325	(992)
Income tax income recognised in profit or loss	(34,845)	(25,147)

In the Material Event Disclosure dated March 26, 2021, as a result of the procedural tax review regarding the technical transactions, including the mergers of the companies in the past, 91.441 thousand TL has been requested to be canceled and the judicial process regarding the issue continues. According to the opinion of the Company Management; Regarding the other transactions, the continuation of the legal process and the finalization accordingly, the possibility of the exit of the economic benefit resources, the opinions of the company legal consultants and tax experts, 31 March 2021 in some summary period, no provision in the financial statements in the interim financial statements. no provision has been made.

### NOTE 23 - EARNINGS PER SHARE

The weighted average number of shares and earnings per share is as follows:

Earnings/(loss) per share	March 31, 2021	March 31, 2020
Weighted average number of shares	208,037	208,037
Net loss for the period for the equity holders of the parent	65,648	50,366
Earnings per share	0.32	0.24

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

### NOTE 24 - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

#### **Financial Risk Factors**

Foreign currency risk management

### Foreign currency risk

Transactions in foreign currencies expose the Company to foreign currency risk. Exchange rate exposures are managed within approved policy parameters utilising forward foreign exchange contracts. The carrying amounts of the Group's foreign currency denominated monetary assets and monetary liabilities at the reporting date are as follows:

### March 31, 2021

	TRY Equivalent			
	(Functional currency)	USD	EUR	GBP
1. Trade receivables	109,484	11,836	1,119	
2a. Monetary financial assets	403,197	3,210	38,509	7
2b. Non monetary financial assets	36,677	1,986	2,056	4
3. Other	5,073	1,960	519	7
4. Current Assets	554,431	17,032	42,203	11
6b. Non monetary financial assets	26,077	3,132	42,203	11
7. Other	20,077	3,132	2	-
8. Non-current assets	26,098	3,132	2	_
9. Total assets	580,529	20,164	42,205	11
10. Trade payables	(25,781)	(2,763)	(284)	11
11a. Financial liabilities (loans)	(179,619)	(2,703)	(18,377)	-
11a. Financial habilities (leasing)	(92,675)	(893)	(8,721)	-
11c. Lease Liabilities	(18,395)	(693)	(1,882)	-
	(75,598)	(3,920)	(4,393)	(2)
12a. Other monetary liabilities  13. Current liabilities	` ' '	(3,920) ( <b>7,576</b> )	` ' '	(2)
	(392,068)	(7,570)	(33,657)	(2)
15a. Financial liabilities (loans)	(70.280)	(912)	(6.500)	-
15b. Financial liabilities (leasing) 15c. Lease Liabilities	(70,389)	(813)	(6,509)	-
	(57,599)	(012)	(5,893)	-
17. Non-current liabilities	(127,988)	(813)	(12,402)	(2)
18. Total liabilities	(520,056)	(8,389)	(46,059)	(2)
19. Net assets / liability position of				
off-balance sheet derivatives (19a-19b)	-	-	-	-
19a. Off balance sheet foreign currency				
derivative assets	-	-	-	-
19b. Off balance sheet foreign currency				
derivative liabilities	-	-	-	-
20. Net foreign currency asset			(A.O.A.)	
liability position (9+18+19)	60,473	11,775	(3,854)	9
21. Monetary Items Net Foreign				
Currency Asset/Liability Position	,	<b></b>	,, ,,,,	_
(1+2a+10+11+12a+14+15+16a)	(7,375)	6,657	(6,431)	5

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS **AS AT MARCH 31, 2021**

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

### NOTE 24 - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Continued)

**December 31, 2020** 

	TRY Equivalent (Functional	
	currency)	USD
1. Trade receivables	93,743	11,708
2a. Monetary financial assets	288,602	2,726
2b. Non monetary financial assets	41,783	2,782
3. Other	3,845	55
4. Current Assets	427,973	17,271
6b. Non monetary financial assets	22,990	3,132

**GBP** 

3

4

**EUR** 

866

29,814

2,367

20. I toli iliolictary ilitaliciai assets	11,703	2,702	2,507	•
3. Other	3,845	55	382	-
4. Current Assets	427,973	17,271	33,429	7
6b. Non monetary financial assets	22,990	3,132	-	-
7. Other	27	-	3	-
8. Non-current assets	23,017	3,132	3	-
9. Total assets	450,990	20,403	33,432	7
10. Trade payables	(22,966)	(2,747)	(311)	-
11a. Financial liabilities (loans)	(165,376)	-	(18,359)	-
11b. Financial liabilities (leasing)	(87,529)	(881)	(8,999)	-
11c. Lease Liabilities	(16,331)	-	(1,813)	-
12a. Other monetary liabilities	(67,214)	(3,740)	(4,414)	-
13. Current liabilities	(359,416)	(7,368)	(33,896)	-
15a. Financial liabilities (loans)	(408,833)	-	(45,386)	-
15b. Financial liabilities (leasing)	(83,864)	(1,010)	(8,487)	-
15c. Lease Liabilities	(57,560)	-	(6,390)	-
17. Non-current liabilities	(550,257)	(1,010)	(60,263)	-
18. Total liabilities	(909,673)	(8,378)	(94,159)	-
19. Net assets / liability position of				
off-balance sheet derivatives (19a-19b)	-	-	-	-
19a. Off balance sheet foreign currency				
derivative assets	-	-	-	-
19b. Off balance sheet foreign currency				
derivative liabilities	-	-	-	-
20. Net foreign currency asset				
liability position (9+18+19)	(458,683)	12,025	(60,727)	7
21. Monetary Items Net Foreign				
<b>Currency Asset/Liability Position</b>				
(1+2a+10+11+12a+14+15+16a)	(527,328)	6,056	(63,479)	3

### Foreign currency sensitivity

The Group is exposed to foreign exchange risk arising primarily from USD and EUR.

The following table details the Group's sensitivity to a 20% increase and decrease against the relevant foreign currencies. 20% is the sensitivity rate used when reporting foreign currency risk internally to key management personnel and represents management's assessment of the possible change in foreign exchange rates. The sensitivity analysis includes only outstanding foreign currency denominated monetary items and adjusts their translation at the period end for a 20% change in foreign currency rates. The sensitivity analysis includes external loans as well as loans to foreign operations within the Group where the denomination of the loan is in a currency other than the currency of the lender or the borrower. A positive number below indicates an increase in profit/loss or equity where the TRY strengthens 20% against the relevant currency. For a 20% weakening of the TRY against the relevant currency, there would be a comparable impact on the profit before tax or equity, and the balances would be negative.

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2021

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

### NOTE 24 - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Continued)

March 31, 2021	Profit/Loss		
In the case of US dollar gaining 20% value against TRY	Valuation of foreign currency	Devaluation o foreign currency	
<ul><li>1 - USD net asset/(liability)</li><li>2- Portion hedged against USD risk (-)</li></ul>	19,608	(19,608)	
3- USD net effect (1 +2)	19,608	(19,608)	
In the case of EUR gaining 20% value against TRY			
4 - EUR net asset/(liability) 5 - Portion hedged against EUR risk (-)	(7,534)	7,534	
6- EUR net effect (4+5)	(7,534)	7,534	
TOTAL (3 + 6)	12,074	(12,074)	
December 31, 2020	Profit/Loss		
In the case of US dollar gaining 20% value against TRY	Valuation of foreign currency	Devaluation of foreign currency	
1 - USD net asset/(liability) 2- Portion hedged against USD risk (-)	17,654	(17,654)	
3- USD net effect (1 +2)	17,654	(17,654)	
In the case of EUR gaining 20% value against TRY			
4 - EUR net asset/(liability) 5 - Portion hedged against EUR risk (-)	(109,405)	109,405	
6- EUR net effect (4+5)	(109,405)	109,405	
Total (3+6)	(91,751)	91,751	

## NOTE 25 - EVENTS AFTER THE REPORTING PERIOD

Board of Directors has approved the consolidated financial statements and delegated authority for publishing it on 6 May 2021.

In accordance with the regulation numbered 7316, published in Official Gazette numbered 31462 on 22 April 2021, corporate tax rate in Turkey for the year 2021 has been increased from 20% to 25%, for the year 2022 to 23%. The amendment is effective as of 1 January 2021. As the change has been announced after the reporting period, it is considered as a non-adjusting event according to IAS 10 and the Group continued to use 20% as of the reporting date and related amendment will be reflected in consolidated financial statements as of 30 June 2021.

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS **AS AT MARCH 31, 2021**

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

### APPENDIX I EARNINGS BEFORE INTEREST TAXES DEPRECIATION AND AMORTISATION ("EBITDA")

Interest, Tax, Depreciation and Amortization ("EBITDA") is calculated by the Group Management with the addition of the period's depreciation and amortization, financial income and expenses, other adjustments and tax deductions to net loss before tax.

The EBITDA calculation movements for the period ended March 31, 2021 and March 31, 2020 are as follow:

EBITDA CALCULATION	March 31, 2021	March 31, 2020
		_
i. Net loss before tax	114,726	86,517
ii. Depreciation and amortization of tangible and intangible		
fixed assets including non-cash provisions related to assets		
such as goodwill	72,855	62,474
iii. Total net finance expenses, net of interest income	117,991	103,310
iv. Fx gains/losses, net under finance expenses	9,098	68,444
v. Fair value differences of derivative instruments (Note 21)	-	(11,287)
vi. Extraordinary (income)/expenses	18,503	4,401
vii. Rediscount income/expense (net imputed interest)	(1,453)	656
viii. Gain on bargain purchase price	· -	(81,980)
viii. Legal case provision expenditures which are reflected to		
financial statements by the general accounting principles;	5,560	(191)
xi. Unused vacation pay provision expenses which are reflected to		
financial statements by the general accounting principles;	4,491	888
x. Retirement pay provision expenses which are reflected to		
financial statements by the general accounting principles;	3,927	2,014
xi. Doubtful receivables provision expenses which are reflected to		
financial statements by the general accounting principles;	258	67
xii. Non cash sale and lease back expenses which are reflected to		
financial statements by the general accounting principles (Note 3);	197	197
xiii. (Income)/expenses from investment operations;	(232)	(384)
EDITO A	245 021	225 126
EBITDA	345,921	235,126
TFRS 16 Lease payment effect	(75,281)	(67,113)
Adjusted EBITDA	270,640	168,013

.....